Residual beta-cell function in diabetes children followed and diagnosed in the TEDDY study compared to community controls

Pediatric Diabetes

Volumn 18, Issue 8, 2017, Pages 794-802

  Steck, Andrea K ^a   Larsson, Helena Elding ^b   Liu, Xiang ^c   Veijola, Riitta ^d   Toppari, Jorma ^e,f   Hagopian, William A ^g   Haller, Michael J ^h   Ahmed, Simi ⁱ   Akolkar, Beena ^j   Lernmark, Åke ^b   Rewers, Marian J ^a   Krischer, Jeffrey P ^c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g UNIVERSITY OF WASHINGTON   (United States)

^h UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

ⁱ Immunology of T1D   (United States)

^j NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

more..

Author keywords

HbA1c; pediatric diabetes; preservation of C peptide; prospective study; type 1 diabetes

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT;

ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; BLOOD; CASE CONTROL STUDY; HEALTH SURVEY; PRESCHOOL CHILD; SECRETION (PROCESS);

C-PEPTIDE; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN-SECRETING CELLS; MALE; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES;

EID: 85011604859     PISSN: 1399543X     EISSN: 13995448     Source Type: Journal    
DOI: 10.1111/pedi.12485     Document Type: Article

References (37)

1. Barker JM, Goehrig SH, Barriga K, et al. Clinical characteristics of children diagnosed with type 1 diabetes through intensive screening and follow-up. Diabetes Care. 2004;27(6):1399-1404.
2. Triolo TM, Chase HP, Barker JM. Diabetic subjects diagnosed through the diabetes prevention trial-type 1 (DPT-1) are often asymptomatic with normal A1c at diabetes onset. Diabetes Care. 2009;32(5):769-773.
3. Elding LH, Vehik K, Gesualdo P, et al. Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease. Pediatr Diabetes. 2014;15(2):118-126.
4. Lundgren M, Sahlin A, Svensson C, et al. Reduced morbidity at diagnosis and improved glycemic control in children previously enrolled in DiPiS follow-up. Pediatr Diabetes. 2014;15(7):494-501.
5. Winkler C, Schober E, Ziegler AG, Holl RW. Markedly reduced rate of diabetic ketoacidosis at onset of type 1 diabetes in relatives screened for islet autoantibodies. Pediatr Diabetes. 2012;13(4):308-313.
6. Elding Larsson H, Vehik K, Bell R, et al. Reduced prevalence of diabetic ketoacidosis at diagnosis of type 1 diabetes in young children participating in longitudinal follow-up. Diabetes Care. 2011;34(11):2347-2352.
7. Greenbaum C, Palmer JP, Kuglin B, Kolb H. Insulin autoantibodies measured by radioimmunoassay methodology are more related to insulin-dependent diabetes mellitus than those measured by enzyme-linked immunosorbent assay: results of the Fourth International Workshop on the Standardization of Insulin Autoantibody Measurement. J Clin Endocrinol Metab. 1992;74(5):1040-1044.
8. Baekkeskov S, Aanstoot H-J, Christgau S, et al. Identification of the 64 K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase [published appears in Nature 1990 Oct 25;347(6295):782]. Nature. 1990;347(6289):151-156.
9. Gianani R, Rabin DU, Verge CF, et al. ICA512 autoantibody radioassay. Diabetes. 1995;44:1340-1344.
10. Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci USA. 2007;104(43):17040-17045.
11. TEDDY Study Group. The Environmental Determinants of Diabetes in the Young (TEDDY) Study. Ann N Y Acad Sci. 2008;1150:1-13.
12. Ziegler AG, Rewers M, Simell O, et al. Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA. 2013;309(23):2473-2479.
13. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care. 2015;38(10):1964-1974.
14. Steffes MW, Sibley S, Jackson M, Thomas W. Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care. 2003;26(3):832-836.
15. Lachin JM, McGee P, Palmer JP, Group DER. Impact of C-peptide preservation on metabolic and clinical outcomes in the diabetes control and complications trial. Diabetes. 2014;63(2):739-748.
16. Palmer JP. C-Peptide in the natural history of type 1 diabetes. Diabetes Metab Res Rev. 2009;25(4):325-328.
17. Brown RJ, Sinaii N, Rother KI. Too much glucagon, too little insulin: time course of pancreatic islet dysfunction in new-onset type 1 diabetes. Diabetes Care. 2008;31(7):1403-1404.
18. VanBuecken DE, Greenbaum CJ. Residual C-peptide in type 1 diabetes: what do we really know? Pediatr Diabetes. 2014;15(2):84-90.
19. DiMeglio LA, Cheng P, Beck RW, et al. Changes in beta cell function during the proximate post-diagnosis period in persons with type 1 diabetes. Pediatr Diabetes. 2016;17(4):237-243.
20. Wallensteen M, Dahlquist G, Persson B, et al. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type I (insulin-dependent) diabetic children followed for two years from their clinical diagnosis. Diabetologia. 1988;31:664-669.
21. Greenbaum CJ, Beam CA, Boulware D, et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes. 2012;61(8):2066-2073.
22. Chan CL, Taki I, Dong F, et al. Comparison of metabolic outcomes in children diagnosed with type 1 diabetes through research screening (Diabetes Autoimmunity Study in the Young [DAISY]) versus in the community. Diabetes Technol Ther. 2015;17(9):649-656.
23. Davis AK, DuBose SN, Haller MJ, et al. Prevalence of detectable C-Peptide according to age at diagnosis and duration of type 1 diabetes. Diabetes Care. 2015;38(3):476-481.
24. Kiviniemi M, Hermann R, Nurmi J, et al. A high-throughput population screening system for the estimation of genetic risk for type 1 diabetes: an application for the TEDDY (the Environmental Determinants of Diabetes in the Young) study. Diabetes Technol Ther. 2007;9(5):460-472.
25. Hagopian WA, Erlich H, Lernmark A, et al. The Environmental Determinants of Diabetes in the Young (TEDDY): genetic criteria and international diabetes risk screening of 421 000 infants. Pediatr Diabetes. 2011;12(8):733-743.
26. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37(suppl 1):S81-S90.
27. Bonifacio E, Yu L, Williams AK, et al. Harmonization of glutamic acid decarboxylase and islet antigen-2 autoantibody assays for national institute of diabetes and digestive and kidney diseases consortia. J Clin Endocrinol Metab. 2010;95(7):3360-3367.
28. Torn C, Mueller PW, Schlosser M, Bonifacio E, Bingley PJ. Diabetes antibody standardization program: evaluation of assays for autoantibodies to glutamic acid decarboxylase and islet antigen-2. Diabetologia. 2008;51(5):846-852.
29. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
30. Mortensen HB, Hougaard P, Swift P, et al. New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care. 2009;32(8):1384-1390.
31. Usher-Smith JA, Thompson M, Ercole A, Walter FM. Variation between countries in the frequency of diabetic ketoacidosis at first presentation of type 1 diabetes in children: a systematic review. Diabetologia. 2012;55(11):2878-2894.
32. Hekkala A, Knip M, Veijola R. Ketoacidosis at diagnosis of type 1 diabetes in children in northern Finland: temporal changes over 20 years. Diabetes Care. 2007;30(4):861-866.
33. Rewers A, Dong F, Slover RH, Klingensmith GJ, Rewers M. Incidence of diabetic ketoacidosis at diagnosis of type 1 diabetes in Colorado youth, 1998–2012. JAMA. 2015;313(15):1570-1572.
34. Herold KC, Gitelman SE, Masharani U, et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes. 2005;54(6):1763-1769.
35. Hagopian W, Ferry RJ Jr, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protege trial. Diabetes. 2013;62(11):3901-3908.
36. Bowden SA, Duck MM, Hoffman RP. Young children (<5 yr) and adolescents (>12 yr) with type 1 diabetes mellitus have low rate of partial remission: diabetic ketoacidosis is an important risk factor. Pediatr Diabetes. 2008;9(3 Pt 1):197-201.
37. Abdul-Rasoul M, Habib H, Al-Khouly M. ‘The honeymoon phase’ in children with type 1 diabetes mellitus: frequency, duration, and influential factors. Pediatr Diabetes. 2006;7(2):101-107.